Alpine Immune Sciences to Present at the 42nd Annual J.P. Morgan Healthcare Conference
18 Dicembre 2023 - 10:30PM
Business Wire
Alpine Immune Sciences, Inc. (NASDAQ: ALPN), a leading
clinical-stage immunotherapy company focused on developing
innovative treatments for autoimmune and inflammatory diseases,
today announced that Mitchell Gold, M.D., Executive Chairman and
Chief Executive Officer, will present at the 42nd Annual J.P.
Morgan Healthcare Conference on Wednesday, January 10, 2024 at 7:30
am PT/10:30 am ET, and the Company will participate in one-on-one
investor meetings.
A live webcast of the presentation will be available in the
investor relations section of the Company’s website at
https://ir.alpineimmunesciences.com/events and a replay will be
available on the Company's website for 90 days following the
event.
About Alpine Immune
Sciences
Alpine Immune Sciences is committed to leading a new wave of
immune therapeutics. With world-class research and development
capabilities, a highly productive scientific platform, and a proven
management team, Alpine is seeking to create first- or
best-in-class multifunctional immunotherapies via unique protein
engineering technologies to improve patients’ lives. Alpine has
entered into strategic collaborations with leading global
biopharmaceutical companies and has a diverse pipeline of clinical
and preclinical candidates in development. For more information,
visit www.alpineimmunesciences.com. Follow @AlpineImmuneSci on X
and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231218108214/en/
Media and Investor Relations
Contact: Temre Johnson Alpine Immune Sciences, Inc.
ir@alpineimmunesciences.com media@alpineimmunesciences.com
Grafico Azioni Alpine Immune Sciences (NASDAQ:ALPN)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni Alpine Immune Sciences (NASDAQ:ALPN)
Storico
Da Giu 2023 a Giu 2024
